Involving A Modified Enzyme (e.g., Abzyme, Recombinant, Chemically Altered, Etc.) Patents (Class 435/7.6)
-
Patent number: 8101373Abstract: Truncated fragments of the small fragment of ?-galactosidase are provided that have low affinity for the large fragment of ?-galactosidase and provide for robust signals when two fusion proteins are complexed due to the binding of the proteins to which the ?-galactosidase fragments are fused. The truncated fragments do not interfere with the complexing of the two proteins and allow for the two proteins to function and be responsive to candidate compounds that affect complex formation.Type: GrantFiled: October 10, 2008Date of Patent: January 24, 2012Assignee: Discoverx CorporationInventors: Thomas Scott Wehrman, Keith R. Olson
-
Publication number: 20120003667Abstract: Methods for measuring hetero- and homodimerization of HIV reverse transcriptase (HIV RT) are provided using pairs of tagged probes and cleaving probes. The methods can be used, for example, to screen for modulators of HIV RT dimerization. Also provided are methods of determining whether a compound modulates HIV RT. Further provided are methods of determining whether a compound modulates formation of a complex between a p66 and p51, p66 and p66, or p51 and p55 subunits polypeptides of HIV RT.Type: ApplicationFiled: June 16, 2008Publication date: January 5, 2012Inventors: Soumi Gupta, Rajiv Dua, Douglas McCann
-
Patent number: 8062874Abstract: The present invention provides fusion proteins including a green fluorescent protein inserted into the internal amino acid sequence of a G?s protein and further provides method of using the fusion protein construct to follow activation of a G-protein receptor by a candidate drug.Type: GrantFiled: July 3, 2002Date of Patent: November 22, 2011Assignee: The Board of Trustees of the University of IllinoisInventors: Mark Rasenick, Jiang-zhou Yu
-
Publication number: 20110275596Abstract: Various methods for treating a patient with neoplasia are disclosed, in particular, methods using topoisomerase Ila-preferential poisons, methods using a combination of a topoisomerase Illi-preferential inhibitor and a topoisomerase II poison, and methods using a combination of a topoisomerase II poison and a proteasome inhibitor are disclosed. Novel topoisomerase Ila-preferential poisons are disclosed, particularly, several novel 13-carboline derivatives are identified. Methods for identifying the novel topoisomerase Ila-preferential poisons and methods for identifying the novel topoisomerase EP-preferential inhibitors are also provided herein.Type: ApplicationFiled: December 14, 2010Publication date: November 10, 2011Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Leroy F. Liu, Yi Lisa Lyu, Anna M. Azarova, Johnson Yiu-Nam Lau
-
Publication number: 20110268744Abstract: The present invention provides isolated M. tuberculosis protein that is a putative Ketol-acid reductoisomerase (KARI; SEQ ID NO: 1) and immunogenic peptide fragments thereof, and antibodies produced against the full-length protein and immunogenic peptide fragments for the diagnosis of tuberculosis and/or infection by one or more mycobacteria of the M. tuberculosis complex in humans, for example using an antigen-based sandwich ELISA format. The present invention also provides multianalyte assays in which the KARI-based diagnostic assays of the present invention are multiplexed with the detection of one or more immunogenic epitopes from one or more other proteins of said mycobacteria e.g., anyone of SEQ IDS NOs: 2, 14, 21, 28-29, 36, or 44, including any combinations thereof.Type: ApplicationFiled: May 26, 2009Publication date: November 3, 2011Inventors: Ian Garthwaite, Robyn Lindner, Susanne Pedersen
-
Patent number: 8003341Abstract: The ATP amplification method is a method for amplifying and detecting a very trace amount of exogenous ATP by allowing a fusion protein (PPK-ADK) of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP, to act on a mixture of ATP, AMP, and a polyphosphate compound. Also provided is an ultrasensitive ATP amplification method by which ATP at a single cell level can be amplified and detected, and an ultrasensitive microbial assay based on this ATP amplification method.Type: GrantFiled: April 28, 2010Date of Patent: August 23, 2011Assignee: Japan Science and Technology AgencyInventor: Akio Kuroda
-
Publication number: 20110201024Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.Type: ApplicationFiled: December 21, 2010Publication date: August 18, 2011Applicant: PROMEGA CORPORATIONInventors: Keith V. Wood, Dieter Klaubert, Georgyi V. Los, Robert F. Bulleit, Mark McDougall, Chad Zimprich
-
Patent number: 7977119Abstract: Methods and compositions for generating mixtures of product molecules from an initial chemical array are provided. In the subject methods, a chemical array of surface immobilized first moieties is subjected to cleavage conditions such that a composition of solution phase first moieties is produced. The resultant composition of solution phase first moieties is then contacted with one or more reactants to produce a mixture of product molecules that are different from the first moieties. Also provided are the arrays employed in the subject methods and kits for practicing the subject methods.Type: GrantFiled: December 8, 2004Date of Patent: July 12, 2011Assignee: Agilent Technologies, Inc.Inventors: Mel N. Kronick, Eric M. Leproust
-
Patent number: 7959926Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.Type: GrantFiled: October 17, 2007Date of Patent: June 14, 2011Assignee: Ambrx, Inc.Inventors: Ying Buechler, Ricky Lieu, Michael Ong, Stuart Bussell, Nick Knudsen, Ho Sung Cho
-
Patent number: 7960132Abstract: A measuring device (100a) includes a base body (101) constituting: a sample holding portion (102) configured to hold a test sample containing urea and a material to be detected; and a sample supply port (103) through which the test sample is supplied to the sample holding portion (102). The base body includes an optical measuring portion and a reagent holding portion (111) which are configured to carry out an optical measurement of the test sample held by the sample holding portion (102). The reagent holding portion holds an antibody to the material to be detected and urease which causes hydrolysis of the urea. With this, the present invention provides a measuring device, a measuring apparatus, and a measuring method, each having a simple configuration and capable of reducing measurement errors caused by the urea contained in the test sample and accurately measuring the material to be detected.Type: GrantFiled: February 20, 2009Date of Patent: June 14, 2011Assignee: Panasonic CorporationInventors: Takahiro Nakaminami, Jin Muraoka
-
Publication number: 20110136140Abstract: It has been found that the pattern of recognized topo I epitopes is different between dcSSc, IcSSc and SLE patients. Fragment F4 (amino acid (AA) 450-600) was recognized by all patients tested. Fragment F1 (AA 5-30) and Fragment F8 (AA 350-400) represent characteristic epitopes for dcSSc and SLE, respectively. The invention relates to diagnostic uses and methods as well as kits for use in diagnosis.Type: ApplicationFiled: July 21, 2009Publication date: June 9, 2011Inventors: Péter Németh, Tamás Czömpöly, Tímea Berki, László Czirják
-
Publication number: 20110124011Abstract: The present invention relates to a method for determining SUMOylation and utilizing said SUMOylation patterns for identifying specific interaction between different binding partners. In another aspect, the present invention relates to systems allowing the determination of SUMOylation and for determining specific interaction between binding partners. Furthermore, the present invention relates to vectors and proteins relating to SUMOylation.Type: ApplicationFiled: August 4, 2009Publication date: May 26, 2011Inventors: Rainer Niedenthal, Astrid Jakobs, Jesko Koehnke
-
Patent number: 7939256Abstract: The present invention provides compositions and methods for detecting incorporation of a labeled nucleotide triphosphate onto the growing end of a primer nucleic acid molecule. The method is used, for example, to genotype and sequence a nucleic acid. In a preferred embodiment, the method described herein detects individual NTP molecules.Type: GrantFiled: October 23, 2007Date of Patent: May 10, 2011Assignee: Pacific Biosciences of California, Inc.Inventor: John G. K. Williams
-
Publication number: 20110081660Abstract: The invention provides methods and kits for detecting conformationally altered proteins, such as prions or other proteins associated with disease states, in a sample. The methods comprise selectively capturing and separating complexes of peptide and conformationally altered protein from substances that interfere with detection of such complexes, and preferably amplification of the detection signal b addition of a second double-labeled peptide.Type: ApplicationFiled: February 14, 2006Publication date: April 7, 2011Inventors: Cindy S. Orser, Tao Pan, Jasmeet Sethi
-
Patent number: 7906624Abstract: A multimeric peptidomimetic that comprises two or more monomers is disclosed. The monomers comprise an exocyclic peptide comprising a ring structure, a flexible linker sequence and a multimeric motif. Use of the monomers, a nucleic acid molecule encoding monomers, recombinant expression vectors comprising the nucleic acid molecule and host cells comprising a recombinant expression vector are disclosed. Methods of delivering a drug, a toxin, a nucleic acid molecule, a radionuclide or a detectable compound to a cell are disclosed.Type: GrantFiled: February 18, 2005Date of Patent: March 15, 2011Assignee: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Ramachandran Murali, Hongtao Zhang
-
Patent number: 7892842Abstract: The present application relates to procedures for the determination of the activity of the protease which activates factor VII, also known as factor VII activating protease or FSAP. The application also relates to a method of detecting whether an individual has increased or lowered activity in the protease which activates factor VII compared to at least one standard sample, wherein the increased or lowered activity indicates an increased risk for disease or cardiovascular complications.Type: GrantFiled: June 6, 2008Date of Patent: February 22, 2011Assignee: CSL Behring GmbHInventors: Juergen Roemisch, Annette Feussner, Hans-Arnold Stoehr
-
Publication number: 20110008765Abstract: The present invention generally relates to a combination of the fields of tissue engineering, drug discovery and drug development. It more specifically provides new methods and materials for testing the efficacy and safety of experimental drugs, defining the metabolic pathways of experimental drugs and characterizing the properties (e.g., side effects, new uses) of existing drugs. Preferably, evaluation is carried out in three-dimensional tissue-engineered systems, wherein drug toxicity, metabolism, interaction and/or efficacy can be determined.Type: ApplicationFiled: February 17, 2010Publication date: January 13, 2011Applicants: THE GENERAL HOSPITAL CORPORATION, THE CHARLES STARK DRAPER LABORATORYInventors: Joseph P. Vacanti, Robert Rubin, Wing Cheung
-
Publication number: 20100311072Abstract: The subject matter disclosed and claimed herein concerns measuring the binding affinity of glucokinase (“GK”) using a fluorescence polarization (“FP”) assay. The FP method includes use of modified GK ligands bound to a fluorescent label. Binding affinity is determined by measuring displacement of fluorescent ligand by the known or suspected GK ligands. The subject matter disclosed and claimed herein provides a robust high-throughput FP assay for the determination of binding affinity of ligands to glucokinase. The FP binding assay displayed both glucose and nucleotide dependence, and a useful dynamic range. The binding IC50 data correlated well with GK activation EC50 data.Type: ApplicationFiled: January 28, 2009Publication date: December 9, 2010Inventors: Ramakrishna Seethala, Jessica Leihwa Dong, Kevin M. O'Malley
-
Publication number: 20100313286Abstract: Disclosed are methods for identifying individuals predisposed to essential hypertension and related conditions such as salt sensitivity by detecting the presence of polymorphic or mutant forms of the GRK4 gene, or its expression product. Also disclosed are methods for identifying polymorphic or mutant GRK4s in individuals known to be suffering from such conditions, as well as methods and compositions for conducting drug discovery and therapeutic intervention.Type: ApplicationFiled: December 1, 2008Publication date: December 9, 2010Applicant: Georgetown UniversityInventors: Robin A. Felder, Pedro Jose
-
Publication number: 20100303861Abstract: The invention provides live attenuated avirulent strains of Francisella tularensis, as well as methods for their preparation and use in protecting a mammal against infection with F. tularensis and against tularemia.Type: ApplicationFiled: September 22, 2006Publication date: December 2, 2010Applicant: President and Fellows of Harvard CollegeInventors: Arthur O. Tzianabos, Dennis L. Kasper, Shite Sebastian, Eric Rubin, Simon T. Dillon
-
Publication number: 20100291550Abstract: The invention relates, in part, to methods and compounds that are useful to modulate hair growth in mammals. The invention, in part, also includes nucleic acids, polypeptides, and genetic constructs that may be used to diagnose and treat hair growth disorders, for screening for compounds that modulate hair growth, and for selecting treatment regimens for subjects with hair loss disorders or hair growth conditions. The invention in some aspects also includes kits that may include polypeptides and/or nucleic acids for diagnosis of hair growth disorders and/or for the modulation of hair growth in subjects.Type: ApplicationFiled: October 11, 2007Publication date: November 18, 2010Applicant: University of MassachusettsInventor: Evgeny I. Rogaev
-
Publication number: 20100284988Abstract: The present invention relates to fusion proteins of monoamine oxidase B (MAO B)-green fluorescent protein (GFP) and utilizes “shield effect” to detect the dopamine under physiological condition, providing the reagent and method for dopamine detection.Type: ApplicationFiled: March 15, 2010Publication date: November 11, 2010Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Tzu-Kang Sang, Cheng-Yuan Lin
-
Publication number: 20100256082Abstract: The present invention is directed to methods for screening for metallohydrolase inhibitors using metal binding moieties in combination with targeting moieties.Type: ApplicationFiled: June 12, 2007Publication date: October 7, 2010Applicant: Viamet Pharmaceuticals, Inc.Inventor: Robert J. Schotzinger
-
Patent number: 7781182Abstract: The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes.Type: GrantFiled: January 9, 2006Date of Patent: August 24, 2010Assignee: Rigel Pharmaceuticals, Inc.Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
-
Patent number: 7771961Abstract: Modulation of cytochrome c acetylation, e.g., with a SIR polypeptide, enables interventions that modulate lifespan regulation and cell proliferation, e.g., by modulating apoptosis and/or mitochondrial function such as respiration.Type: GrantFiled: July 10, 2009Date of Patent: August 10, 2010Assignee: Elixir Pharmaceuticals, IncInventors: L. Julie Huber, Jonathan M. Solomon
-
Publication number: 20100190187Abstract: Various embodiments of the present invention provide methods for screening for candidate heart failure compounds employing screening assays effective in identifying agonists or antagonists or ligands of vitamin D receptor mediated pathways implicated in heart failure. Methods are provided for the screening of test compounds that can specifically bind to the vitamin D receptor. Methods for screening for a test compound which modulates the activity of a VDR for the treatment of heart failure, wherein the method comprises: (a) contacting a test compound with VDR in a reaction mixture, wherein the reaction mixture conditions permits the test compound to bind to a VDR, including membrane VDR and nuclear VDR. The binding between the test compound and the VDR is compared to a reference such as Vitamin D3. The modulation of biomarkers after a test compound has bound and activated a VDR are also measured and compared to samples in the absence of test compound.Type: ApplicationFiled: February 14, 2007Publication date: July 29, 2010Applicant: The Regents of the University of Michigan Office of Technology TransferInventors: Robert U. Simpson, Daniel Tishkoff, Karl Nibbelink
-
Publication number: 20100184090Abstract: This invention relates to industrial production of proteins. More specifically, the invention relates to a method for obtaining cells that stably express a protein of interest, even when cultivated in the absence of selective pressure. DHFR is used as a surrogate marker. The transfected cells are not selected based on resistance to a toxic compound, but based on fluorescence as measured by FACS using fluorescent MTX.Type: ApplicationFiled: July 16, 2008Publication date: July 22, 2010Applicant: MERCK SERONO SAInventors: Tara Kristen Crawford McFadd, Meijia Yang
-
Patent number: 7749720Abstract: The invention herein provides a mode of treating metabolic syndrome, which includes Type 2 diabetes mellitus and insulin resistance in human and other subjects by identifying and administering an insulin sensitizing compound which modulates GRK2 function in the insulin signaling pathway. The invention also provides polynucleotides, polypeptides, vectors, cells, tissues and organisms useful in the identification and treatment of metabolic syndrome. A number of desirable insulin sensitizing aspects are achieved by various embodiments of the present invention.Type: GrantFiled: June 17, 2005Date of Patent: July 6, 2010Assignee: The Regents of the University of CaliforniaInventors: Jerrold M. Olefsky, Isao Usui, Takeshi Imamura
-
Patent number: 7745116Abstract: The present invention provides compositions and methods for detecting incorporation of a labeled nucleotide triphosphate onto the growing end of a primer nucleic acid molecule. The method is used, for example, to genotype and sequence a nucleic acid. In a preferred embodiment, the method described herein detects individual NTP molecules.Type: GrantFiled: April 8, 2004Date of Patent: June 29, 2010Assignee: Pacific Biosciences of California, Inc.Inventor: John G. K. Williams
-
Patent number: 7745160Abstract: The ATP amplification method of the present invention is a method for amplifying and detecting a very trace amount of exogenous ATP by allowing a fusion protein (PPK-ADK) of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP, to act on a mixture of ATP, AMP, and a polyphosphate compound. The present invention also provides an ultrasensitive ATP amplification method by which ATP at a single cell level can be amplified and detected, and an ultrasensitive microbial assay based on this ATP amplification method.Type: GrantFiled: July 27, 2004Date of Patent: June 29, 2010Assignee: Japan Science and Technology AgencyInventor: Akio Kuroda
-
Patent number: 7695964Abstract: Compositions and methods are provided for preparing an hsiRNA mixture and for silencing of gene expression in vivo. The composition relates to a mutant RnaseIII. The methods are directed to reacting a preparation of dsRNA with an effective amount of a mutant RNAse III to produce the hsiRNA mixture.Type: GrantFiled: January 21, 2005Date of Patent: April 13, 2010Assignee: New England Biolabs, Inc.Inventors: Claude V. Maina, George Tzertzinis, Sanjay Kumar
-
Patent number: 7695973Abstract: The present invention provides methods for quantitation of glycated protein in a biological sample using a solid support matrix by making a first bound protein measurement total bound protein under conditions where both glycated and non-glycated protein bind to the support in making a second bound protein measurement under conditions where glycated protein is bound to the support and non-glycated protein is not substantially bound. Diagnostic devices and kits comprising the methods of the present invention are also provided.Type: GrantFiled: February 7, 2007Date of Patent: April 13, 2010Assignee: Scripps Laboratories, Inc.Inventors: Ralph P. McCroskey, Cameron E. Melton
-
Patent number: 7691564Abstract: Receptor mediated activation of heterotrimeric G-proteins is visualized in living cells by monitoring fluorescence resonance energy transfer (FRET) between subunits of a G protein fused to cyan and yellow fluorescent proteins. The G-protein heterotrimer rapidly dissociates and reassociates upon addition and removal of cognate ligand. Energy transfer pairs of G-proteins enables direct in situ detection and have applications for drug screening and GPCR de-orphaning.Type: GrantFiled: January 3, 2006Date of Patent: April 6, 2010Assignee: The Johns Hopkins UniversityInventors: Peter N. Devreotes, Chris Janetopoulos
-
Patent number: 7662581Abstract: This invention provides methods of identifying an Eg5 binding ligand. The ligand is identified by using the atomic coordinates of an Eg5 crystal to generate a three dimensional structure. The three dimensional structure is used in molecular modeling techniques and docking experiments to identify ligands that bind to the binding pocket of Eg5. A novel binding pocket is identified. The invention also provides a crystallized Eg5 and ligand complex.Type: GrantFiled: December 20, 2004Date of Patent: February 16, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Dirksen Bussiere, Mark Knapp, Vincent P. Le, Eric Martin
-
Publication number: 20090286261Abstract: An exemplary embodiment may be directed to a fluorescence polarization assay that screens compounds or agents for their affinity to hematopoietic prostaglandin D synthase (H-PGDS) based on their ability to displace a fluorophore-containing detection analyte bound to an enzyme comprising the primary amino acid sequence of H-PGDS. Another exemplary embodiment utilizes an enzyme having a maltose binding protein amino-acid sequence fused with an N-terminus of the enzyme.Type: ApplicationFiled: May 13, 2009Publication date: November 19, 2009Applicant: CAYMAN CHEMICAL COMPANYInventors: Kirk W. Maxey, Jeffrey K. Johnson, Karie L. McGowan, Nisha Palackal, Gregory W. Endres
-
Publication number: 20090275053Abstract: The present invention includes a PCSK9 activity inhibition assay system, kits, compositions and methods. The present invention includes a cell having a first vector capable of expressing a catalytic fragment of PCSK9, a second vector capable of expressing a prodomain of PCSK9 and a V5 protein with a detectable label. The V5 protein forms a fusion protein with the prodomain of PCSK9 and wherein cleavage of the prodomain by the catalytic fragment of PCSK9 releases a detectable signal.Type: ApplicationFiled: April 30, 2008Publication date: November 5, 2009Applicant: Board of Regents, The University of Texas SystemInventors: Jay D. Horton, Markey C. McNutt
-
Patent number: 7575883Abstract: Modulation of cytochrome c acetylation, e.g., with a SIR polypeptide, enables interventions that modulate lifespan regulation and cell proliferation, e.g., by modulating apoptosis and/or mitochondrial function such as respiration.Type: GrantFiled: December 15, 2003Date of Patent: August 18, 2009Assignee: Elixir Pharmaceuticals, Inc.Inventors: L. Julie Huber, Jonathan M. Solomon
-
Patent number: 7575866Abstract: The present invention relates to methods and compositions which utilize binding relationships between detector molecules and their ligands for labeling molecules of interest in vivo. A “target” molecule is linked to a detector molecule (such as a protein or a nucleic acid) and the function and/or location of the target molecule is monitored by binding the detector molecule its ligand, which carries a detectable label. In particular embodiments of the invention, an intracellular fusion protein comprising a target protein and a detector protein is bound to a membrane-permeable, fluorescently-labeled ligand of the detector protein, thereby providing an adjunct or alternative to Green Fluorescent Protein.Type: GrantFiled: September 1, 2005Date of Patent: August 18, 2009Inventors: Virginia Cornish, Michael Sheetz, Larry Miller
-
Patent number: 7569338Abstract: A rapid and convenient method for detecting inflammatory conditions in breast tissue, such as those associated with mastitis, is described. The method comprises measuring the presence and quantity of Serum Amyloid A (SAA) in milk samples obtained from the breast tissue. The amount of SAA present in the milk is positively correlated with the level of inflammation of the breast tissue, and can localize the inflammation to a particular region of the breast organ, such as a specific quadrant of a cow's udder. Test kits and their use in the method are also described.Type: GrantFiled: August 25, 1999Date of Patent: August 4, 2009Assignee: Accuplex, LLC.Inventors: Thomas L. McDonald, Annika Weber
-
Patent number: 7569374Abstract: The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.Type: GrantFiled: December 17, 2007Date of Patent: August 4, 2009Assignee: Merck & Co., Inc.Inventors: Donald J. Graham, Amy L. Simcoe, Steven W. Ludmerer, Osvaldo A. Flores, Robert L. LaFemina
-
Patent number: 7558717Abstract: The present invention relates to human Janus Kinase 3 (JAK3) and JAK3-like binding pockets. The present invention provides a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to JAK3 protein or JAK3 protein homologues, or complexes thereof. The invention also relates to crystallizable compositions and crystals comprising JAK3 kinase domain and JAK3 kinase domain complexed with AMP-PNP.Type: GrantFiled: April 26, 2005Date of Patent: July 7, 2009Assignee: Vertex Pharmaceuticals IncorporatedInventors: Harmon Zuccola, Marc Jacobs, Lovorka Swenson, Kumkum Saxena
-
Patent number: 7547519Abstract: The invention relates to the discovery that a putative gene of Mycobacterium tuberculosis with no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. Since M. tuberculosis has a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854c and now termed “EtaA,” are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.Type: GrantFiled: February 14, 2005Date of Patent: June 16, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Clifton E. Barry, III, Andrea E. DeBarber, Khisimuzi Mdluli, Linda-Gail Bekker
-
Patent number: 7537921Abstract: Variants of Glycoside Hydrolase family 53 galactanases, e.g. variants of the galactanases from strains of Yersinia, Aspergillus, Humicola, Meripilus, Myceliophthora, Thermomyces, Bacillus, Bifidobacterium, Cellvibrio, Clostridium, Pseudomonas, Thermotoga, or Xanthomonas.Type: GrantFiled: December 11, 2003Date of Patent: May 26, 2009Assignee: Novozymes A/SInventors: Leonardo De Maria, Allan Svendsen, Torben Vedel Borchert, Lars Lehmann Hylling Christensen, Sine Larsen, Carsten Ryttersgaard
-
Patent number: 7531337Abstract: A method for modulating the activity of an AMP-forming enzyme (AFE) is disclosed. The method is based upon the novel observation that the activity of these enzymes is controlled by acetylation of the enzymes to inactivate them and de-acetylation of the enzymes to re-activate them. The acetylation of the enzyme occurs at a characteristic lysine residue. Various polypeptides, nucleic acids and other molecules that are related to modulating the AFE activity are also disclosed. Further disclosed are methods of modulating cellular acetyl-CoA or propionyl-CoA levels in bacterial hosts, methods of identifying agents that can modulate the activity of AFE acetylases, and methods of identifying AFE mutants that are insensitive to acetylation regulation.Type: GrantFiled: June 6, 2003Date of Patent: May 12, 2009Assignee: Wisconsin Alumni Research FoundationInventors: Jorge C. Escalante-Semerena, Vincent J. Starai
-
Patent number: 7524642Abstract: Provided are methods and compositions for assaying for ubiquitin agents that are enzymatic components of ubiquitin-mediated proteolysis and, more particularly, methods and compositions for assaying for agents that modulate the activity of such ubiquitin agents.Type: GrantFiled: October 2, 2006Date of Patent: April 28, 2009Assignee: Rigel Pharmaceuticals, Inc.Inventors: Sarkiz D. Issakani, Jianing Huang, Julie Sheung, Todd R. Pray
-
Patent number: 7504230Abstract: The present invention is a cell-based method of identifying a set of signal transduction proteins having an intracellular localization pattern responsive to toxic compounds. The method requires identifying and screening an initial set of signal transduction proteins against a set of toxic compounds, and determining changes in intracellular localization pattern of each of the proteins. Proteins whose changes in intracellular localization pattern are redundant are discarded from the initial set, and new proteins are added to provide a new set of proteins. I repeat the method steps with new sets of proteins until the set of proteins provides me at least 5 principal components with respect to the range of compounds marketed as small organic molecules.Type: GrantFiled: November 13, 2003Date of Patent: March 17, 2009Assignee: Trelolis Bioscience, Inc.Inventor: Lawrence M. Kauvar
-
Patent number: 7479377Abstract: A system is provided an enzyme donor (“ED”) fused a surrogate of a mammalian protein of interest, where the fusion protein has the function of the natural protein. A vector is provided comprising a regulatory region functional in a mammalian host cell, a sequence encoding the ED joined to a multiple cloning site, an enzyme acceptor (“EA”) protein or enzyme acceptor sequence encoding such protein, and substrate for the enzyme formed by ED and EA.Type: GrantFiled: August 27, 2002Date of Patent: January 20, 2009Assignee: DiscoveRx CorporationInventors: Sharon Zhao, Inna Vainshtein, Richard M. Eglen
-
Publication number: 20090017061Abstract: The present invention relates to mycobacterial lipoarabinomannan cap-specific mannosyl transferases and nucleic acid encoding such transferases. The invention further relates to Mycobacteria in which the lipoarabinomannan cap-specific mannosyl transferases have been inactivated and that therefore express mannose cap-deficient lipoarabinomannan. Such Mycobacteria with mannose cap-deficient lipoarabinomannan may be used as more effective vaccines against mycobacterial diseases as they lack the immunosuppressive action of the mannose cap.Type: ApplicationFiled: January 18, 2006Publication date: January 15, 2009Inventors: Bernard Jan Appelmelk, Wilhelmus Bitter, Peter Andre van der Ley
-
Publication number: 20090010911Abstract: The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. It has been previously reported by the inventors that a substrate SH2 domain docking mechanism apart from the kinase active site is required for appropriate tyrosine phosphorylation by these tyrosine kinases. According to the invention, it has been discovered that Cyclophilin A, the target of drugs such as cyclosporin A, mediates its regulatory effects by interacting with this remote SH2 domain, making modulation of this interaction possible for regulation and improved therapeutic intervention.Type: ApplicationFiled: May 7, 2008Publication date: January 8, 2009Applicant: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Amy H. ANDREOTTI, Raji E. JOSEPH, Lie MIN
-
Publication number: 20080311592Abstract: A method of altering the conformation of a polypeptide having a known three-dimensional structure is described. The method comprises attaching a first end of a polymer to a first portion of the polypeptide, attaching a second end of the polymer to a second portion of the polypeptide, and altering the mechanical tension of the polymer, thereby altering the conformation of the polypeptide. The alteration of the conformation of the polypeptide may increase or decrease the binding affinity of the polypeptide for a substrate bound by the polypeptide, or alter the catalytic rate of an enzyme. Typically, the polymer is a polynucleotide or polypeptide.Type: ApplicationFiled: January 20, 2006Publication date: December 18, 2008Applicant: The Regents of the University of CaliforniaInventors: Giovanni Zocchi, Brian Choi